Matthew Segall PhD
CEO and Company Director
Matt has a Master of Science in computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica's ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI's ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.
CSO and Company Director
After graduating with a degree in Mathematics in 1995 Ed joined GlaxoWellcome working as part of a pioneering team building predictive pharmaceutical tools. He developed the first graphical user-interfaces for working with predictive models which were adopted globally within GlaxoWellcome. He was a core member of the team which established the UK operation of Camitro in 2001 and remained with that company (now operating within BioFocus DPI following merger and acquisition) until 2008. During this time he designed and built the StarDrop software and, in 2009, co-founded Optibrium.
Head of Commercial Operations
Nick graduated with a degree in Applied Biochemistry in 1993 before joining the Medical Research Council working on protein folding within Cambridge University's Chemistry Department and the Laboratory for Molecular Biology (LMB) until 2001. After this, Nick helped establish the ADME/PK laboratory of Camitro and remained part of the operational team (within BioFocus) until 2009 when he joined the sales and marketing team as Associate Director of Business Development, Europe. Nick joined Optibrium in 2012.
Peter Hunt PhD
Director of Computational Chemistry
Peter trained as a synthetic organic chemist, gaining a degree and PhD at Imperial College, University of London. He moved into the computational chemistry field during a postdoc at the 3D Centre in Australia, focussing on peptidomimetic design to address HIV protease inhibition and mimicry of bioactive peptides such as the Conotoxins. He returned to the UK in 1994 to join the CADD group of Merck & Co Inc and then moved to Novartis 2006. Prior to joining Optibrium in 2014, Peter lead the UK CADD group efforts in drug discovery and development research in the Neuroscience, Respiratory and Gastrointestinal disease areas. He is an inventor on over 20 patents, as well as a former chair of the TRIPOS User group and currently Secretary of the UK-QSAR committee.
Nick Boyes PhD
Non-executive Company Director
Nick Boyes graduated as a Pharmacist from the University of Toronto before obtaining a PhD degree in Pharmaceutical Chemistry from the University of London. He held senior positions in drug discovery, clinical research and marketing with Astra Pharmaceuticals Inc. in the United States and Europe for 18 years until 1985, after which he founded the UK drug development company, Innovata (now part of Vectura PLC). He was a director of ML Laboratories PLC from 1993 until 2005 and has been a director of two other UK public companies.